IL194628A0 - Use of escitalopram for improving cognition - Google Patents

Use of escitalopram for improving cognition

Info

Publication number
IL194628A0
IL194628A0 IL194628A IL19462808A IL194628A0 IL 194628 A0 IL194628 A0 IL 194628A0 IL 194628 A IL194628 A IL 194628A IL 19462808 A IL19462808 A IL 19462808A IL 194628 A0 IL194628 A0 IL 194628A0
Authority
IL
Israel
Prior art keywords
escitalopram
improving cognition
cognition
improving
Prior art date
Application number
IL194628A
Other languages
English (en)
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of IL194628A0 publication Critical patent/IL194628A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL194628A 2006-05-02 2008-10-07 Use of escitalopram for improving cognition IL194628A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200600621 2006-05-02
PCT/DK2007/050050 WO2007124757A2 (en) 2006-05-02 2007-04-30 Use of escitalopram for improving cognition

Publications (1)

Publication Number Publication Date
IL194628A0 true IL194628A0 (en) 2009-08-03

Family

ID=38134951

Family Applications (1)

Application Number Title Priority Date Filing Date
IL194628A IL194628A0 (en) 2006-05-02 2008-10-07 Use of escitalopram for improving cognition

Country Status (15)

Country Link
EP (1) EP2026793A2 (zh)
JP (1) JP2009535367A (zh)
KR (1) KR20090009820A (zh)
CN (1) CN101426494A (zh)
AR (1) AR060732A1 (zh)
AU (1) AU2007245983A1 (zh)
BR (1) BRPI0710230A2 (zh)
CA (1) CA2651002A1 (zh)
EA (1) EA200870491A1 (zh)
IL (1) IL194628A0 (zh)
MX (1) MX2008013911A (zh)
NO (1) NO20085009L (zh)
TW (1) TW200812993A (zh)
WO (1) WO2007124757A2 (zh)
ZA (1) ZA200808632B (zh)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60327634D1 (de) 2002-08-22 2009-06-25 Dainippon Sumitomo Pharma Co Mittel zur behandlung des integrationsdysfunktionssyndroms
EP1637530A4 (en) 2003-06-23 2009-04-01 Dainippon Sumitomo Pharma Co THERAPEUTIC AGENT FOR SENILE DEMENTIA
EP1726952A4 (en) 2004-02-20 2008-06-18 Dainippon Sumitomo Pharma Co METHOD FOR IN VIVO SCREENING OF A THERAPEUTIC FOR A MEMORY / LEARNING FUNCTION THROUGH SCHIZOPHRENIA
NO2185155T3 (zh) * 2007-08-03 2018-03-03
EP2236138A1 (en) * 2009-03-30 2010-10-06 PharmaNeuroBoost N.V. Low dose pipamperone in treating mood and anxiety disorders
US8258139B2 (en) 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders
EP3069718A1 (en) * 2015-03-17 2016-09-21 Universidade do Minho Citalopram or escitalopram for use in the treatment of neurodegenerative diseases
CA3047354A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
PL3338768T3 (pl) 2016-12-20 2020-05-18 Lts Lohmann Therapie-Systeme Ag Transdermalny system terapeutyczny zawierający asenapinę
CA3067938A1 (en) 2017-06-26 2019-01-03 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and silicone acrylic hybrid polymer
CA3101420A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
KR102051624B1 (ko) * 2018-11-30 2019-12-02 아밀로이드솔루션 주식회사 트리플루프로마진 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 퇴행성 뇌질환 치료용 약학 조성물
CN109464436A (zh) * 2019-01-10 2019-03-15 高智玉 西酞普兰或艾司西酞普兰分别和喹硫平联合在制备治疗精神障碍类疾病的复方制剂中的应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK213290D0 (da) * 1990-09-06 1990-09-06 Lundbeck & Co As H Treatment of cerebrovascular disorders
SE9803157D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
SE9803158D0 (sv) * 1998-09-16 1998-09-16 Astra Ab A new composition
US6617361B2 (en) * 1999-11-05 2003-09-09 Be Able, Llc Behavior chemotherapy
DE60028841T2 (de) * 2000-12-01 2006-12-28 Be Able, Llc Verhaltenschemotherapie
WO2002076461A1 (en) * 2001-03-26 2002-10-03 Serdar Murat Dursun Combination of reboxetine and citalopram
CA2445843A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram
US20050014848A1 (en) * 2002-01-23 2005-01-20 Pfizer Inc. Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors
WO2004010932A2 (en) * 2002-07-30 2004-02-05 Peter Migaly Combination therapy for depression, prevention of suicide, and varous medical and psychiatric conditions
CN100349885C (zh) * 2002-12-23 2007-11-21 H·隆德贝克有限公司 依他普仑氢溴酸盐及其制备方法
EP1670454A1 (en) * 2003-09-04 2006-06-21 H. Lundbeck A/S The combination of a serotonin reuptake inhibitor and loxapine
JP2009511607A (ja) * 2005-10-14 2009-03-19 ハー・ルンドベック・アクチエゼルスカベット エスシタロプラムおよびブプロピオンを含有する安定な医薬製剤
EP1954257A4 (en) * 2005-10-14 2009-05-20 Lundbeck & Co As H METHOD FOR TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM WITH A LOW-DOSED COMBINATION OF ESCITALOPRAM AND BUPROPION
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram

Also Published As

Publication number Publication date
CA2651002A1 (en) 2007-11-08
WO2007124757A2 (en) 2007-11-08
JP2009535367A (ja) 2009-10-01
KR20090009820A (ko) 2009-01-23
AU2007245983A1 (en) 2007-11-08
AR060732A1 (es) 2008-07-10
TW200812993A (en) 2008-03-16
EP2026793A2 (en) 2009-02-25
NO20085009L (no) 2008-12-16
CN101426494A (zh) 2009-05-06
BRPI0710230A2 (pt) 2011-08-02
WO2007124757A3 (en) 2008-07-24
EA200870491A1 (ru) 2009-04-28
ZA200808632B (en) 2009-12-30
MX2008013911A (es) 2008-11-12

Similar Documents

Publication Publication Date Title
ZA200808632B (en) Use of escitalopram for improving cognition
EP2068864A4 (en) THERAPEUTIC USES OF UROLITHINS
IL202664A (en) Processes for Preparation of 3-Dihlomethyl-1-Methyl-1H-Pyrazole-4-Carbaldehyde and Intermediates
ZA200900886B (en) Use of azabicyclo hexane derivatives
IL197632A0 (en) Use of jam-c binding compounds
IL196606A0 (en) Use of escin
GB0705854D0 (en) Methods of construction
IL197966A0 (en) Use of modified cyclosporin
TWI320362B (en) Enhanced imaging of features
EP1931370A4 (en) USE OF DES-ASPARTATE-ANGIOTENSIN I
GB0700179D0 (en) Use of epoxidised compounds
SI2038260T1 (sl) Stereoselektivna sinteza (S)-1-metil-3-fenilpiperazina
HU0500947D0 (en) Composition for treatment of paradontosis
PL381142A1 (pl) Sposób otrzymywania glicydolu
GB0624439D0 (en) Technique for treatment of gall-and kidney-stones
GB0602857D0 (en) The treatment of sialorrhoea
HUP0500948A2 (en) Composition for treatment of diabeticus paradontosis
GB0612370D0 (en) Uses of (S)-clenbuterol
GB0604575D0 (en) Construction of inductive components
PL1886669T3 (pl) Preparat o działaniu immunotropowym na bazie fosfoglukanu do leczenia przerostu migdałka gardłowego
GB2443891B (en) Process for the purification of meloxicam
GB0625602D0 (en) Treatment of sialorrhoea
IL198836A0 (en) Processes for preparation of 9-haloacetamidomidominocyclines
TWM311768U (en) Improved structure of A-ladder
GB0602858D0 (en) The treatment of sialorrhoea